Trials / Recruiting
RecruitingNCT06467539
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Chang Gung Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DAOIB plus AO | oral, for 24 weeks |
| DRUG | DAOIB plus placebo | oral, for 24 weeks |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2024-06-21
- Last updated
- 2026-03-19
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06467539. Inclusion in this directory is not an endorsement.